
generated by the enzyme family of sphingosine kinases (SPHK) and degraded by different phosphatases or lyases.

In one aspect, there is provided a compound of the formula I, in any of its stereoisomeric forms, or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them,



I

wherein

A is chosen from NH, O and S;

R^1 is chosen from $(C_1\text{-}C_6)$-alkyl, $(C_2\text{-}C_6)$-alkenyl, $(C_2\text{-}C_6)$-alkynyl, $(C_3\text{-}C_7)$-cycloalkyl-C_uH_{2u}- and Het-C_vH_{2v}-, wherein u and v are chosen from 1 and 2, or R^1 is a residue of a saturated or unsaturated, 3-membered to 10-membered, monocyclic or bicyclic ring which comprises 0, 1, 2, 3 or 4 identical or different ring heteroatoms chosen from N, O and S, wherein one or two of the ring nitrogen atoms can carry a hydrogen atom or a $(C_1\text{-}C_4)$-alkyl substituent and one or two of the ring sulfur atoms can carry one or two oxo groups, and wherein the residue of a ring is optionally substituted on one or more ring carbon atoms by identical or different substituents R^{11};

R^2 is chosen from phenyl and a residue of an aromatic, 5-membered to 6-membered monocyclic heterocycle which comprises 1, 2 or 3 identical or different ring heteroatoms chosen from N, O and S, wherein one of the ring nitrogen atoms can carry a hydrogen atom or a substituent R^{21}, and wherein the phenyl and residue of an aromatic heterocycle are optionally substituted on one or more ring carbon atoms by identical or different substituents R^{22};

R^{11} is chosen from halogen, (C_1-C_4)-alkyl, (C_3-C_7)-cycloalkyl, hydroxy, (C_1-C_4)-alkyloxy, oxo, (C_1-C_4)-alkyl-$S(O)_m$-, amino, (C_1-C_4)-alkylamino, di((C_1-C_4)-alkyl)amino, (C_1-C_4)-alkylcarbonylamino, (C_1-C_4)-alkylsulfonylamino, nitro, cyano, (C_1-C_4)-alkylcarbonyl, aminosulfonyl, (C_1-C_4)-alkylaminosulfonyl and di((C_1-C_4)-alkyl)aminosulfonyl;

R^{21} is chosen from (C_1-C_4)-alkyl, (C_3-C_7)-cycloalkyl-C_wH_{2w}- and oxy, wherein w is chosen from 0, 1 and 2;

R^{22} is chosen from halogen, hydroxy, (C_1-C_4)-alkyl-, (C_1-C_4)-alkyloxy, (C_1-C_4)-alkyl-$S(O)_m$-, amino, nitro, cyano, hydroxycarbonyl, (C_1-C_4)-alkyloxycarbonyl, aminocarbonyl, aminosulfonyl, R^{23} and R^{23}-O-;

R^{23} is a residue of a saturated 3-membered to 7-membered, monocyclic or bicyclic ring which comprises 0, 1, 2, 3 or 4 identical or different ring heteroatoms chosen from N, O and S, wherein one or two of the ring nitrogen atoms can carry a hydrogen atom or a (C_1-C_4)-alkyl substituent and one of the ring sulfur atoms can carry one or two oxo groups, and wherein the residue of a ring is optionally substituted on one or more ring carbon atoms by identical or different substituents R^{24};

R^{24} is chosen from halogen, (C_1-C_4)-alkyl, hydroxy and oxo;

Het is a residue of a saturated, 4-membered to 7-membered, monocyclic heterocycle which comprises 1 or 2 identical or different ring heteroatoms chosen from N, O and S and which is bonded via a ring carbon atom, wherein the residue of a heterocycle is optionally substituted by one or more identical or different substituents chosen from fluorine and (C_1-C_4)-alkyl;


m is chosen from 0, 1 and 2, wherein all numbers m are independent of each other;

wherein all cycloalkyl groups, independently of each other and independently of any other substituents, are optionally substituted by one or more identical or different substituents chosen from fluorine and (C_1-C_4)-alkyl;

wherein all alkyl, C_uH_{2u}, C_vH_{2v}, C_wH_{2w}, alkenyl and alkynyl groups, independently of each other and independently of any other substituents, are optionally substituted by one or more fluorine substituents;

with the exception of the compounds 5-methylmercapto-2-phenyl-oxazolo[5,4-α]-pyrimidine and 5-ethylmercapto-2-phenyloxazolo-[5,4-α]pyrimidine.

In one aspect, there is provided a process for the preparation of a compound of the formula I as defined above, comprising reacting a compound of the formula II with a compound of the formula III,



II I

wherein the groups A, R^1 and R^2 in the compounds of the formulae II and III are defined as in the compounds of the formula I and additionally functional groups can be present in protected form or in the form of a precursor group, and the group L^1 is a halogen atom or a group of the formula -S(O)-Alk or -$S(O)_2$-Alk wherein Alk is (C_1-C_4)-alkyl.

In one aspect, there is provided a pharmaceutical composition, comprising at least one compound of the formula I as defined above or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, and a pharmaceutically acceptable carrier.

In one aspect, there is provided a compound of the formula I as defined above or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, for use as a pharmaceutical.


In one aspect, there is provided a compound of the formula I as defined above or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, for the treatment of wound healing disorders.

In one aspect, there is provided a compound of the formula I as defined above or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them for wound healing.

In one aspect, there is provided a compound of the formula I as defined above or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them for wound healing in diabetics.

In one aspect, there is provided a compound of the formula I as defined above or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them, for the treatment of diabetic foot syndrome.

A subject of the present invention is an oxazolopyrimidine compound of the formula I, in any of its stereoisomeric forms, or a mixture of stereoisomeric forms in any ratio, or a physiologically acceptable salt thereof, or a physiologically acceptable solvate of any of them,



I

wherein

A is chosen from NH, O and S;

R^1 is chosen from $(C_1\text{-}C_6)$-alkyl, $(C_2\text{-}C_6)$-alkenyl, $(C_2\text{-}C_6)$-alkynyl, $(C_3\text{-}C_7)$-cycloalkyl-C_uH_{2u}- and Het-C_vH_{2v}-, wherein u and v are chosen from 1 and 2, or R^1 is a residue of a saturated or unsaturated, 3-membered to 10-membered, monocyclic or bicyclic ring which comprises 0, 1, 2, 3 or 4 identical or different ring heteroatoms chosen from N, O and S, wherein one or two of the ring nitrogen atoms can carry a hydrogen atom or a $(C_1\text{-}C_4)$-alkyl substituent and one or two of the ring sulfur atoms can carry one or two oxo groups, and wherein the residue of a ring is optionally substituted on one or more ring carbon atoms by identical or different substituents R^{11};

R^2 is chosen from phenyl and a residue of an aromatic, 5-membered to 6-membered monocyclic heterocycle which comprises 1, 2 or 3 identical or different ring heteroatoms chosen from N, O and S, wherein one of the ring nitrogen atoms can carry a hydrogen atom or a substituent R^{21}, and wherein the phenyl and residue of an aromatic heterocycle are optionally substituted on one or more ring carbon atoms by identical or different substituents R^{22};